Matches in SemOpenAlex for { <https://semopenalex.org/work/W2270036667> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2270036667 endingPage "615" @default.
- W2270036667 startingPage "613" @default.
- W2270036667 abstract "In a previous phase II study with a dose-intensive weekly cisplatin schedule for six cycles, we observed a partial response in 5 of 14 patients with pleural mesothelioma. However, response duration was short (median 6 months). Since oral etoposide may theoretically be synergistic to cisplatin, we performed a phase II study with the combination of both drugs.Twenty-five chemo-naive patients with pleural mesothelioma were treated with cisplatin 70 mg/m2 days 1-8-15 and days 29-36-43 in combination with oral etoposide 50 mg days 1-15 and days 29-43. Patients with stable disease, or better, continued treatment with oral etoposide 50 mg/m2/day days 1-21 every 28 days RESULTS All patients were evaluable for response and toxicity. Complete response was observed in one patient and partial responses in 5 patients (RR% 24%; 95% Cl: 10%-45%) for a median duration of 30 weeks. Twelve patients had stable disease. The response status never improved during maintenance treatment with oral etoposide. Most patients tolerated the regimen very well. Toxicity was manly haematologic with leukocytopenia causing treatment delays in 8 patients. Ototoxicity grade 1 or 2 was observed in 8 patients, neurotoxicity grade 1 in 9 patients and nephrotoxicity grade 1 in 1 patient.Frequently administered cisplatin in combination with oral etoposide has a moderate but definite activity in pleural mesothelioma." @default.
- W2270036667 created "2016-06-24" @default.
- W2270036667 creator A5006479854 @default.
- W2270036667 creator A5011819733 @default.
- W2270036667 creator A5021449457 @default.
- W2270036667 creator A5037696756 @default.
- W2270036667 creator A5043032829 @default.
- W2270036667 creator A5045167907 @default.
- W2270036667 creator A5055323618 @default.
- W2270036667 creator A5067526861 @default.
- W2270036667 date "1995-07-01" @default.
- W2270036667 modified "2023-09-28" @default.
- W2270036667 title "Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma" @default.
- W2270036667 cites W1825053022 @default.
- W2270036667 cites W1842684227 @default.
- W2270036667 cites W2127597055 @default.
- W2270036667 cites W2132371987 @default.
- W2270036667 cites W2288673339 @default.
- W2270036667 cites W2291585146 @default.
- W2270036667 cites W2306856286 @default.
- W2270036667 doi "https://doi.org/10.1093/oxfordjournals.annonc.a059253" @default.
- W2270036667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8573543" @default.
- W2270036667 hasPublicationYear "1995" @default.
- W2270036667 type Work @default.
- W2270036667 sameAs 2270036667 @default.
- W2270036667 citedByCount "40" @default.
- W2270036667 countsByYear W22700366672012 @default.
- W2270036667 countsByYear W22700366672015 @default.
- W2270036667 countsByYear W22700366672016 @default.
- W2270036667 crossrefType "journal-article" @default.
- W2270036667 hasAuthorship W2270036667A5006479854 @default.
- W2270036667 hasAuthorship W2270036667A5011819733 @default.
- W2270036667 hasAuthorship W2270036667A5021449457 @default.
- W2270036667 hasAuthorship W2270036667A5037696756 @default.
- W2270036667 hasAuthorship W2270036667A5043032829 @default.
- W2270036667 hasAuthorship W2270036667A5045167907 @default.
- W2270036667 hasAuthorship W2270036667A5055323618 @default.
- W2270036667 hasAuthorship W2270036667A5067526861 @default.
- W2270036667 hasBestOaLocation W22700366671 @default.
- W2270036667 hasConcept C126322002 @default.
- W2270036667 hasConcept C141071460 @default.
- W2270036667 hasConcept C142724271 @default.
- W2270036667 hasConcept C2776694085 @default.
- W2270036667 hasConcept C2777407522 @default.
- W2270036667 hasConcept C2778119113 @default.
- W2270036667 hasConcept C2778239845 @default.
- W2270036667 hasConcept C2780873365 @default.
- W2270036667 hasConcept C2781413609 @default.
- W2270036667 hasConcept C2909463153 @default.
- W2270036667 hasConcept C29730261 @default.
- W2270036667 hasConcept C71924100 @default.
- W2270036667 hasConcept C90924648 @default.
- W2270036667 hasConceptScore W2270036667C126322002 @default.
- W2270036667 hasConceptScore W2270036667C141071460 @default.
- W2270036667 hasConceptScore W2270036667C142724271 @default.
- W2270036667 hasConceptScore W2270036667C2776694085 @default.
- W2270036667 hasConceptScore W2270036667C2777407522 @default.
- W2270036667 hasConceptScore W2270036667C2778119113 @default.
- W2270036667 hasConceptScore W2270036667C2778239845 @default.
- W2270036667 hasConceptScore W2270036667C2780873365 @default.
- W2270036667 hasConceptScore W2270036667C2781413609 @default.
- W2270036667 hasConceptScore W2270036667C2909463153 @default.
- W2270036667 hasConceptScore W2270036667C29730261 @default.
- W2270036667 hasConceptScore W2270036667C71924100 @default.
- W2270036667 hasConceptScore W2270036667C90924648 @default.
- W2270036667 hasIssue "6" @default.
- W2270036667 hasLocation W22700366671 @default.
- W2270036667 hasLocation W22700366672 @default.
- W2270036667 hasOpenAccess W2270036667 @default.
- W2270036667 hasPrimaryLocation W22700366671 @default.
- W2270036667 hasRelatedWork W1973686872 @default.
- W2270036667 hasRelatedWork W2009580345 @default.
- W2270036667 hasRelatedWork W2021093326 @default.
- W2270036667 hasRelatedWork W2085562186 @default.
- W2270036667 hasRelatedWork W2252341082 @default.
- W2270036667 hasRelatedWork W2270036667 @default.
- W2270036667 hasRelatedWork W2306856286 @default.
- W2270036667 hasRelatedWork W2373165702 @default.
- W2270036667 hasRelatedWork W2417697013 @default.
- W2270036667 hasRelatedWork W2767052226 @default.
- W2270036667 hasVolume "6" @default.
- W2270036667 isParatext "false" @default.
- W2270036667 isRetracted "false" @default.
- W2270036667 magId "2270036667" @default.
- W2270036667 workType "article" @default.